List of Excipients in Branded Drug AZATHIOPRINE

« Back to Dashboard

Generic Drugs Containing AZATHIOPRINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	azathioprine	0378-1005	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	azathioprine	0378-1005	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	azathioprine	0378-1005	POVIDONE K30
Mylan Pharmaceuticals Inc	azathioprine	0378-1005	STARCH, CORN
Mylan Pharmaceuticals Inc	azathioprine	0378-1005	STEARIC ACID
NCS HealthCare of KY Inc dba Vangard Labs	azathioprine	0615-7568	ANHYDROUS LACTOSE

What are the Most Frequently-Used Excipients in AZATHIOPRINE?

# Of NDCs	Excipient
7	ANHYDROUS LACTOSE
12	CROSCARMELLOSE SODIUM
20	LACTOSE MONOHYDRATE
27	MAGNESIUM STEARATE
19	POVIDONE
6	POVIDONE K30

Azathioprine Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Azathioprine is an established, multisource immunosuppressant with limited core patent protection and low barriers to conventional generic entry. The strongest commercial opportunities are differentiated oral dosage forms, pediatric and dysphagia-friendly products, lactose-free formulations, improved moisture protection, and lower-exposure manufacturing systems. Excipient selection should prioritize chemical stability, content uniformity at relatively low doses, tablet robustness, dissolution performance, and safe handling of a cytotoxic immunosuppressant.

What is the commercial status of azathioprine?

Azathioprine is a purine antimetabolite used in transplant medicine, autoimmune disease, and inflammatory disorders. It is converted in vivo to 6-mercaptopurine and downstream thiopurine metabolites that suppress immune-cell proliferation.

The drug is marketed primarily as immediate-release oral tablets. Injectable azathioprine products have had limited commercial relevance compared with oral therapy. Major use areas include:

Market segment	Principal use	Commercial characteristics
Solid-organ transplant	Maintenance immunosuppression	Chronic use; adherence and tablet availability matter
Rheumatology	Rheumatoid arthritis and related autoimmune disease	Generic price pressure
Gastroenterology	Crohn's disease and ulcerative colitis	Pediatric and liquid-dosing needs
Dermatology	Autoimmune and inflammatory skin disease	Lower-volume specialty use
Neurology and other specialties	Selected immune-mediated disorders	Clinician-directed, often off-label

Azathioprine is generally available as 25 mg, 50 mg, 75 mg, and 100 mg tablets in markets where the full strength range is commercialized. Product availability varies by country and manufacturer. The reference product Imuran has faced extensive generic competition, while Azasan and generic azathioprine products have supported additional U.S. supply channels.

The market is mature. Price competition limits the value of a conventional “me-too” tablet. A differentiated product must solve a practical problem involving administration, tolerability, excipient exclusion, stability, supply reliability, or specialty distribution.

What excipients are used in azathioprine tablets?

Azathioprine tablet excipients vary by manufacturer and strength. Public labeling for marketed products identifies common functional categories such as diluents, binders, disintegrants, lubricants, and coating materials. Representative excipients include lactose or lactose monohydrate, microcrystalline cellulose, starch, croscarmellose sodium, povidone, magnesium stearate, hypromellose, and colorants. Exact compositions must be confirmed from the applicable product label and regulatory filing because formulations can differ by strength and market.

Excipient class	Representative materials	Function	Key azathioprine considerations
Diluent	Lactose monohydrate, microcrystalline cellulose, starch	Provides tablet mass and compressibility	Lactose may exclude patients with intolerance or create positioning limitations
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength	Excess binder can slow disintegration and dissolution
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes tablet breakup	Useful when direct compression produces dense tablets
Lubricant	Magnesium stearate, stearic acid, sodium stearyl fumarate	Reduces ejection force and tooling adhesion	Excess magnesium stearate can impair wetting and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow	Helps control die fill and low-dose content uniformity
Film former	Hypromellose, polyvinyl alcohol	Protects tablet and improves handling	Coating must not delay immediate-release performance unless intended
Plasticizer	Polyethylene glycol, triethyl citrate	Improves coating flexibility	Selection affects moisture transmission and coating robustness
Opacifier or colorant	Titanium dioxide, iron oxides, approved dyes	Identification and light protection	Must comply with current jurisdictional requirements

The most important formulation issue is not the novelty of the excipient. It is the interaction among excipient levels, powder flow, tablet compression, dissolution, and stability. Azathioprine products should be evaluated for assay, related substances, dissolution, content uniformity, friability, hardness, moisture uptake, and photostability.

Which excipient risks are most important for azathioprine?

Chemical stability and moisture control

Azathioprine has limited aqueous solubility and can be sensitive to formulation and environmental conditions. Water activity, microenvironmental pH, granulation liquid, drying conditions, and packaging can affect degradation and dissolution.

A dry process, such as direct compression or dry granulation, may reduce exposure to water during manufacture. Wet granulation can still be viable, but it requires control of granulation endpoint, drying temperature, residual moisture, and hold times.

Commercial development should establish:

• Drug-excipient compatibility under accelerated and long-term conditions.
• Degradation pathways in the presence of water, heat, light, and oxygen.
• The effect of alkaline or acidic microenvironments.
• Moisture transmission through the bottle, blister, and closure system.
• Stability after opening, particularly for multidose packaging.

A low-moisture formulation alone does not establish superior stability. The finished product, packaging system, and manufacturing process must be evaluated together under ICH stability conditions.

Content uniformity at low strengths

The 25 mg tablet creates a greater content-uniformity challenge than the 75 mg or 100 mg tablet. Poor powder segregation can produce variable drug content, especially where the active pharmaceutical ingredient has different particle-size or density characteristics from the diluent.

Risk controls include:

• Particle-size engineering or controlled milling.
• Geometric dilution during blending.
• Low-shear blending that limits segregation.
• Use of microcrystalline cellulose or a comparable carrier with suitable flow.
• In-process blend and tablet weight controls.
• Stratified sampling across compression runs.

A formulation that performs well at 100 mg may not transfer directly to a 25 mg strength. Bracketing must be justified through formulation and process data.

Lubrication and dissolution

Magnesium stearate is widely used but can create hydrophobic surfaces when over-lubricated or blended for excessive time. This can delay wetting and dissolution. Sodium stearyl fumarate may offer a different lubrication profile, but substitution requires comparative evaluation of tablet strength, ejection force, dissolution, and stability.

The critical control is the relationship between lubricant concentration and blending time. A robust formulation should not depend on a narrow lubrication window that is difficult to reproduce at commercial scale.

Lactose exclusion

Lactose-containing formulations are common in oral tablets, but lactose-free positioning can create a practical differentiation point. Potential target groups include patients with perceived lactose intolerance, institutions seeking simplified excipient policies, and caregivers seeking products with fewer formulation restrictions.

A lactose-free product is not automatically clinically superior. The commercial value depends on:

• Whether competing strengths already exclude lactose.
• The prevalence of relevant intolerance or avoidance behavior.
• Label clarity.
• Supply availability.
• Price relative to conventional generics.

Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and starch-based systems can support lactose-free formulations, subject to dissolution and manufacturability testing.

What formulation strategies offer the strongest commercial opportunity?

Lactose-free immediate-release tablets

This is the most practical near-term strategy. It requires limited clinical differentiation if the product remains pharmaceutically equivalent and meets applicable regulatory requirements.

A candidate formulation could use:

• Microcrystalline cellulose as the principal diluent.
• Croscarmellose sodium or crospovidone as the disintegrant.
• Povidone or dry binder technology if additional tablet strength is required.
• Sodium stearyl fumarate or controlled magnesium stearate lubrication.
• A low-moisture film coating with a moisture-barrier package.

The value proposition is simple: reliable supply, a broad strength range, and a formulation without lactose or unnecessary colorants.

Pediatric oral suspension

Pediatric use is a more differentiated opportunity than another adult tablet. A liquid product could support children who cannot swallow tablets and patients receiving weight-based dosing.

The principal development risks are substantial:

• Azathioprine has limited aqueous solubility.
• Suspension uniformity must remain acceptable throughout the labeled in-use period.
• Sedimentation and redispersibility must be controlled.
• Preservative selection must be compatible with the active ingredient.
• Palatability may be difficult because thiopurine compounds can have an unpleasant taste.
• The product must address safe handling of a hazardous or immunosuppressive drug.

A ready-to-use suspension may have better adherence potential than extemporaneous compounding, but it requires more extensive stability, microbiological, dosing-device, and human-factors work. An oral powder for reconstitution could reduce shipping volume and improve stability, but it transfers preparation risk to pharmacies or caregivers.

Dysphagia-friendly dosage forms

Orally disintegrating tablets, mini-tablets, dispersible tablets, and sachets could address swallowing difficulty. The principal limitation is dose flexibility. Azathioprine is commonly prescribed in weight-based or individualized regimens, making a single high-strength orally disintegrating tablet less useful than a flexible multiparticulate or low-strength platform.

A dispersible 25 mg product could have greater value than an adult 100 mg orally disintegrating tablet because it supports titration. Any product intended to be dispersed in water must demonstrate dose recovery from the container, acceptable dispersion time, uniformity, and chemical stability during the administration window.

Modified-release or enteric-coated products

Modified release is a higher-risk opportunity. Azathioprine dosing is generally managed through systemic exposure and clinical response rather than a known need for prolonged release. An enteric-coated product would need a clinically defensible rationale, such as improved gastrointestinal tolerability, and would require comparative pharmacokinetic and clinical evidence.

A coating that delays release without improving clinical performance would add cost and regulatory complexity without a clear market advantage.

Unit-dose and adherence-oriented packaging

Unit-dose blister packaging can reduce medication errors, improve portability, and create a supply proposition for transplant centers and specialty pharmacies. It can also limit repeated exposure during handling.

Packaging should be designed around:

• Moisture protection.
• Light protection where justified by stability data.
• Child resistance.
• Clear strength differentiation.
• Minimized tablet handling.
• Compatibility with hazardous-drug handling practices.

For chronic transplant use, packaging reliability may have more commercial value than a novel excipient system.

How should excipient selection address safety and handling?

Azathioprine is an immunosuppressive and cytotoxic drug. Occupational controls should be considered throughout dispensing, manufacturing, packaging, and compounding. The National Institute for Occupational Safety and Health has included azathioprine among hazardous drugs requiring exposure-control measures in applicable workplace settings (NIOSH, 2023).

Excipient strategy should therefore be linked to containment strategy. Direct compression may reduce solvent handling, but it does not remove powder-exposure risk. Granulation, milling, tablet dedusting, coating, and packaging can generate occupational exposure.

Commercial development should assess:

• Closed or contained transfer systems.
• Local exhaust ventilation.
• Dust extraction during compression and dedusting.
• Personnel protection.
• Cleaning validation and cross-contamination controls.
• Waste management.
• Breakage and tablet-dispersion risk during packaging.

A formulation that reduces friability and dusting can create both manufacturing and occupational benefits. These benefits should be demonstrated with process data rather than inferred from excipient choice.

What patents protect azathioprine formulations?

The original composition-of-matter protection for azathioprine is expired. Conventional immediate-release azathioprine tablets are therefore exposed to generic competition in major markets.

The relevant intellectual-property landscape is more likely to involve:

• Formulation patents.
• Liquid suspension compositions.
• Taste-masking systems.
• Modified-release dosage forms.
• Manufacturing processes.
• Packaging or containment systems.
• Method-of-use claims in selected jurisdictions.

These rights are unlikely to block ordinary generic tablets unless a specific formulation or use is incorporated into the product. Current Orange Book listings, patent certifications, and regulatory exclusivity should be checked for each applicant and strength before launch planning. The FDA Orange Book is the controlling public source for listed U.S. patents and exclusivity associated with approved drug products (FDA, n.d.-a).

What is the Orange Book status of azathioprine?

Azathioprine is a multisource product with long-established generic availability. The core active ingredient does not create a current patent barrier. The relevant question is whether a particular listed product has unexpired patents or exclusivity associated with a differentiated formulation or method of use.

For a conventional immediate-release generic, Paragraph IV litigation risk is generally lower than for newer small-molecule products with active formulation patents. A sponsor still must review the current Orange Book, approved labels, listed patents, ANDA filing status, and any relevant district-court or Federal Circuit proceedings before selecting a filing strategy.

When does azathioprine lose exclusivity?

Azathioprine lost practical market exclusivity decades ago. The commercial market is now governed by generic competition, manufacturing economics, distribution access, and product differentiation rather than by pending core patent expiration.

There is no meaningful biosimilar pathway because azathioprine is a small-molecule drug, not a biologic. Biosimilar competition is therefore irrelevant. Competitive pressure comes from ANDA-approved tablets, authorized generics where applicable, compounded liquids, and hospital or specialty-pharmacy sourcing.

Which companies are challenging or competing with azathioprine products?

Competition is fragmented among generic manufacturers and label holders. The principal competitive categories are:

Competitor type	Product form	Strategic effect
Large generic manufacturers	Immediate-release tablets	Lowest unit cost and broad distribution
Specialty generic suppliers	Selected strengths or pack sizes	Supply continuity and niche contracting
Compounding pharmacies	Extemporaneous oral liquids	Flexible dosing but variable availability and handling
Hospital suppliers	Institutional packs and unit doses	Procurement-driven competition
Branded or legacy labels	Established tablet products	Residual prescriber and payer recognition

A new entrant should avoid relying on brand recognition. The strongest entry case is a differentiated product with a clear formulary or patient-use benefit.

What FDA regulatory pathway applies to a new azathioprine product?

A conventional immediate-release tablet would generally be developed as an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to a suitable reference product. A new dosage form, suspension, modified-release product, or clinically differentiated formulation may require a 505(b)(2) strategy or another regulatory pathway depending on the product design and claims.

Key regulatory workstreams include:

• Selection of the reference listed drug.
• Strength and dosage-form matching.
• Inactive-ingredient justification.
• Dissolution method development.
• Bioequivalence strategy.
• Stability and packaging.
• Extractables and leachables for liquid products.
• Dose-delivery validation.
• Hazardous-drug manufacturing controls.

FDA’s Inactive Ingredient Database can support preliminary excipient selection, but prior use at a particular route, dosage form, and maximum daily exposure does not eliminate the need for product-specific safety and quality assessment (FDA, n.d.-b).

How strong is the commercial opportunity?

The opportunity is moderate for a differentiated product and weak for an undifferentiated tablet. A practical ranking is:

Opportunity	Commercial potential	Development risk	Main value driver
Lactose-free immediate-release tablet	Moderate	Low to moderate	Formulary and patient-excipient differentiation
Reliable 25/50/75/100 mg strength portfolio	Moderate	Moderate	Supply and dosing coverage
Unit-dose moisture-protective packaging	Moderate	Low	Institutional procurement and handling
Pediatric oral suspension	Moderate to high	High	Unmet administration need
Dispersible or mini-tablet product	Moderate	Moderate to high	Weight-based dosing and dysphagia
Modified-release product	Low to moderate	High	Requires clinical rationale
Novel excipient without user benefit	Low	Moderate	Weak differentiation

Revenue exposure is likely to be concentrated in volume rather than price. Conventional azathioprine tablets have low pricing power, while a specialty liquid or pediatric product may support higher gross margins but lower volume and greater regulatory expense.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve formulation and commercialization rights than ownership of core azathioprine patents. Potential structures include:

• Contract development of a pediatric suspension.
• Regional licensing of a lactose-free tablet.
• Co-development with a specialty pharmacy.
• Manufacturing partnerships with containment-capable facilities.
• Distribution agreements for transplant and pediatric channels.
• Technology licensing for taste masking, dry suspension, or unit-dose packaging.

The most attractive partner profile is a manufacturer with existing hazardous-drug infrastructure, ANDA or 505(b)(2) experience, and access to transplant, gastroenterology, and pediatric prescribers.

What generic launch scenarios should companies consider?

A conventional tablet launch can be executed through a low-cost, high-volume strategy, but it will face rapid price erosion and possible supply-driven competition. A differentiated launch can pursue one of three paths:

1. Launch a full strength portfolio with lactose-free positioning and robust supply.
2. Launch a 25 mg or pediatric-focused product where dosing flexibility is more valuable.
3. Launch a liquid or dispersible dosage form through specialty distribution.

The third path has the greatest differentiation but also the highest CMC and regulatory burden. A staged strategy can begin with tablets and use the same supplier, containment system, and brand platform for a liquid product.

Key Takeaways

• Azathioprine is a mature generic market with no meaningful core patent barrier.
• Excipient strategy should focus on stability, content uniformity, dissolution, and low-dusting manufacture.
• Lactose-free immediate-release tablets are the lowest-risk differentiation opportunity.
• Pediatric suspension, dispersible tablets, and mini-tablets offer greater commercial upside but require additional CMC and regulatory work.
• Modified-release products need a clear clinical rationale and are not attractive solely as patent-extension vehicles.
• There is no biosimilar risk because azathioprine is a small molecule.
• Current Orange Book listings, ANDA records, and litigation should be reviewed before a U.S. filing or launch decision.
• Packaging and occupational controls are commercially relevant because azathioprine requires hazardous-drug handling considerations.
• The strongest business case combines a complete strength portfolio, reliable supply, excipient exclusion where meaningful, and specialty-channel access.

FAQs

Is lactose-free azathioprine commercially differentiated?

Yes, but the differentiation is incremental. It can support formulary, patient-preference, and excipient-avoidance positioning, but it will not by itself overcome substantial generic price competition.

Can azathioprine be formulated as a stable oral liquid?

Yes, an oral liquid or suspension is technically possible, but solubility, sedimentation, taste, preservative compatibility, chemical stability, dose uniformity, and hazardous handling require extensive development work.

Is azathioprine suitable for an orally disintegrating tablet?

It may be suitable, particularly at lower strengths, but taste, dose flexibility, tablet loading, and rapid dissolution must be addressed. A dispersible or mini-tablet format may provide greater clinical utility.

Does azathioprine have biosimilar competition?

No. Azathioprine is a small-molecule drug regulated through generic drug pathways rather than biosimilar pathways.

What is the most defensible formulation patent strategy for azathioprine?

A patent strategy based on a clinically useful liquid, dispersible, taste-masked, or stability-enhanced product is more defensible than a minor change to a standard immediate-release tablet. The claims must be supported by reproducible product performance and a credible patient or manufacturing benefit.

References

1. European Medicines Agency. (2013). Guideline on pharmaceutical development of medicines for paediatric use. https://www.ema.europa.eu/

2. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. https://www.ich.org/

3. International Council for Harmonisation. (2009). ICH Q9: Quality risk management. https://www.ich.org/

4. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings, 2023. Centers for Disease Control and Prevention. https://www.cdc.gov/niosh/

5. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (n.d.-b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

7. U.S. Food and Drug Administration. (n.d.-c). DailyMed: Azathioprine product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

8. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.